The LUMC has received large-scale funding to support new stem cell research.
The Leiden University Medical Center (LUMC) will receive a total of €150 million in their partnership with reNEW consortium for innovative research based on stem cells. Thank to these investments, LUMC can keep working on new treatments for patients with chronis diseases and strengthen their position as an international center for research and innovation.
the LUMC and reNEW partnership
ReNEW is an international collaboration specialising in stem cell research. Within this partnership, Leiden University Medical Centre (LUMC) works alongside the University of Copenhagen and the Murdoch Children's Research Institute in Melbourne. This partnership has now been awarded €150 million to develop new treatments for diseases for which there are currently no effective treatment options. This funding is provided by the Novo Nordisk Foundation, which has previously granted funding and will continue to do so until 2031. LUMC has a long history of stem cell research and regenerative medicine is one of its strategic focus areas.
Stem cells
Stem cells are unique, unspecialised human cells that can divide indefinitely and develop into different specialised cell types, such as muscle, blood or brain cells. This means they can help to replace or repair damaged tissue in a process known as regenerative medicine. They have the potential to be used to treat diseases such as Parkinson's, diabetes and spinal cord injuries. Thanks to this new function, LUMC can launch new projects, develop technologies, train young scientists and translate laboratory discoveries into treatments for patients more quickly. This paves the way for solutions for patients who currently have limited treatment options.
